Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mobocertinib
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Mobocertinib is an oral small molecule kinase inhibitor specifically designed to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations in non-small cell lung cancer (NSCLC). These mutations are associated with resistance to standard EGFR inhibitors and a poorer prognosis. Mobocertinib binds irreversibly to the mutant EGFR at cysteine 797 in the active site, leading to sustained inhibition of EGFR enzymatic activity and suppression of tumor cell proliferation. It was developed for use in adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. Mobocertinib received accelerated approval from the US FDA in 2021 but was voluntarily withdrawn worldwide following results from a phase III trial that did not meet its primary endpoint.
- Brand names
- Exkivity
- Other names
- mobocertinibTAK-788TAK788TAK 788Exkivity
02
Targets
Epidermal growth factor receptor (EGFR) exon 20 insertion mutantEGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ABCB1 (P-glycoprotein)ABCG2 (ATP-binding cassette sub-family G member 2)
Beyond the preview
Go deeper on mobocertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mobocertinib.